<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen (paracetamol): Usual oral dosing for adults with pain or inflammation and selected characteristics</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen (paracetamol): Usual oral dosing for adults with pain or inflammation and selected characteristics</h1>
<div class="graphic"><div class="figure"><div class="ttl">Nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen (paracetamol): Usual oral dosing for adults with pain or inflammation and selected characteristics</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup> <colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Usual analgesic dose (oral)</td> <td class="subtitle1">Maximum dose per day</td> <td class="subtitle1">Selected characteristics</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Nonselective NSAIDs<sup>*</sup></td> </tr> <tr> <td class="subtitle3_left" colspan="4">Acetic acids</td> </tr> <tr> <td class="indent2"><span class="nowrap_whitespace">Diclofenac<sup>¶</sup></span></td> <td>50 mg every 8 to 12 hours</td> <td> <p>150 mg</p> <p>For rheumatoid arthritis, labeling in United States permits up to 200 mg</p> Approved maximum in Canada is 100 mg</td> <td> <ul> <li>Dosing for free-acid preparation differs from doses listed here for sodium or potassium salts; refer to Lexicomp drug monograph</li> </ul> </td> </tr> <tr> <td class="indent2">Etodolac</td> <td>200 to 400 mg every 6 to 8 hours</td> <td>1000 mg</td> <td> <ul> <li>Relative COX-2 selectivity and minimal effect on platelet function at lower total daily dose of 600 to 800 mg</li> </ul> </td> </tr> <tr> <td class="indent2">Indomethacin</td> <td>25 to 50 mg every 8 to 12 hours</td> <td> <p>150 mg</p> For rheumatologic conditions, labeling in United States permits up to 200 mg</td> <td> <ul> <li>Used for treatment of acute gout and certain types of headache</li> <li>Potent inhibitory effects on kidney prostaglandin synthesis</li> <li>More frequently associated with CNS side effects (eg, headache, altered mental status) compared with other NSAIDs</li> </ul> </td> </tr> <tr> <td class="indent2">Sulindac</td> <td>150 to 200 mg every 12 hours</td> <td>400 mg</td> <td> <ul> <li>Rarely used</li> <li>More frequently associated with hepatic inflammation than other NSAIDs</li> <li>Metabolites implicated in the formation of renal calculi</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="4">Fenamates</td> </tr> <tr> <td class="indent2">Meclofenamate (meclofenamic acid)</td> <td> <p>50 mg every 4 to 6 hours</p> <p>or</p> 100 mg 3 times daily up to 6 days for dysmenorrhea</td> <td>400 mg</td> <td> <ul> <li>Used for treatment of dysmenorrhea</li> <li>Relatively higher incidence of GI side effects</li> </ul> </td> </tr> <tr> <td class="indent2">Mefenamic acid</td> <td> <p>250 mg every 6 hours</p> <p>or</p> 500 mg 3 times daily</td> <td> <p>1000 mg</p> For dysmenorrhea, up to 1500 mg</td> <td> <ul> <li>Used for treatment of dysmenorrhea; not indicated for treatment of chronic pain or inflammation</li> <li>Do not exceed 3 days (dysmenorrhea) to 7 days (acute pain) of use</li> <li>Less potent antiinflammatory effect</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="4">Nonacidic</td> </tr> <tr> <td class="indent2">Nabumetone</td> <td>1000 mg once to twice daily</td> <td>2000 mg</td> <td> <ul> <li>Relative COX-2 selectivity and minimal effect on platelet function at daily dose ≤1000 mg</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="4">Oxicams</td> </tr> <tr> <td class="indent2" rowspan="2"><span class="nowrap_whitespace">Meloxicam<sup>Δ</sup></span></td> <td class="border_bottom_white">7.5 to 15 mg once daily (conventional tablet, oral suspension)</td> <td class="border_bottom_white">15 mg (conventional tablet, oral suspension)</td> <td rowspan="2"> <ul> <li>Long duration of effect; relatively slow onset</li> <li>Relative COX-2 selectivity and minimal effect on platelet function at lower daily dose of 7.5 mg</li> </ul> </td> </tr> <tr> <td>5 to 10 mg once daily (capsule)</td> <td>10 mg (capsule)</td> </tr> <tr> <td class="indent2">Piroxicam</td> <td>10 to 20 mg once daily</td> <td>20 mg</td> <td> <ul> <li>Long-acting alternative for treatment of chronic pain and inflammation poorly responsive to other NSAIDs</li> <li>Prescribing generally limited to specialists with experience in treatment of chronic pain and inflammation</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="4">Propionic acids</td> </tr> <tr> <td class="indent2">Fenoprofen</td> <td>200 mg every 4 to 6 hours or 400 to 600 mg every 6 to 8 hours</td> <td>3200 mg</td> <td> <ul> <li>More frequently associated with acute interstitial nephritis and nephrotic <span class="nowrap_whitespace">syndrome<sup>[1]</sup></span></li> </ul> </td> </tr> <tr> <td class="indent2">Flurbiprofen</td> <td>50 mg every 6 hours or 100 mg every 8 to 12 hours</td> <td>300 mg</td> <td> </td> </tr> <tr> <td class="indent2"><span class="nowrap_whitespace">Ibuprofen<sup>Δ</sup></span></td> <td>400 mg every 4 to 6 hours or 600 to 800 mg every 6 to 8 hours</td> <td>3200 mg (acute), 2400 mg (chronic)</td> <td> <ul> <li>Shorter-acting alternative to naproxen; useful in patients without cardiovascular risks</li> </ul> </td> </tr> <tr> <td class="indent2">Ketoprofen</td> <td>50 mg every 6 hours or 75 mg every 8 hours</td> <td>300 mg</td> <td> </td> </tr> <tr> <td class="indent2" rowspan="2">Naproxen</td> <td class="border_bottom_white">Base: 250 to 500 mg every 12 hours or 250 mg every 6 to 8 hours</td> <td class="border_bottom_white">Base: 1250 mg (acute); 1000 mg (chronic); may increase to 1500 mg during a disease flare</td> <td rowspan="2"> <ul> <li>Often preferred by UpToDate for treatment of acute or chronic pain and inflammation in patients without relevant comorbidities or risks</li> <li>Higher dose (eg, 500 mg base twice daily) may have less cardiovascular toxicity than comparable doses of other <span class="nowrap_whitespace">NSAIDs;<sup>[2]</sup></span> refer to UpToDate topic review of cardiovascular effects of nonselective NSAIDs</li> <li>Naproxen sodium has a faster onset than naproxen base</li> </ul> </td> </tr> <tr> <td>Naproxen sodium: 275 to 550 mg every 12 hours or 275 mg every 6 to 8 hours</td> <td>Naproxen sodium: 1375 mg (acute); 1100 mg (chronic); may increase to 1650 mg during a disease flare</td> </tr> <tr> <td class="indent2">Oxaprozin</td> <td>1200 mg once daily</td> <td>1200 mg or 1800 mg depending on body weight (refer to Lexicomp drug monograph)</td> <td> <ul> <li>Prolonged half-life (41 to 55 hours); requires several days of treatment to reach full effect</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="4">Salicylate (acetylated)</td> </tr> <tr> <td class="indent2">Aspirin</td> <td>325 to 1000 mg every 4 to 6 hours</td> <td>4000 mg</td> <td> <ul> <li>Not commonly used for chronic pain and inflammation</li> <li>High daily doses have been used as antiinflammatory therapy; such use is limited by toxicity</li> <li>Irreversibly inhibits platelet function</li> <li>Refer to appropriate UpToDate clinical topics and Lexicomp drug monograph for other uses</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="4">Salicylates (nonacetylated)</td> </tr> <tr> <td class="indent2">Diflunisal</td> <td>500 mg every 8 to 12 hours</td> <td>1500 mg</td> <td rowspan="3"> <ul> <li>No significant effect on platelet function at usual doses</li> <li>Relatively lower GI bleeding risk than other nonselective NSAIDs at usual doses</li> <li>May be tolerated at lower daily doses by adults with AERD or pseudoallergic reactions (eg, asthma, rhinosinusitis); refer to UpToDate topic reviews of allergic and pseudoallergic reactions to NSAIDs</li> </ul> </td> </tr> <tr> <td class="indent2">Magnesium salicylate</td> <td>1160 mg every 6 hours</td> <td>4640 mg</td> </tr> <tr> <td class="indent2">Salsalate</td> <td>1000 mg every 8 to 12 hours or 1500 mg every 12 hours</td> <td>3000 mg</td> </tr> <tr> <td class="subtitle2_left" colspan="4">COX-2 selective NSAIDs</td> </tr> <tr> <td class="indent1">Celecoxib</td> <td>200 mg daily or 100 mg every 12 hours</td> <td>400 mg</td> <td> <ul> <li>Less risk of GI toxicity relative to nonselective NSAIDs; benefit negated by low-dose aspirin, which may require concurrent gastroprotection</li> <li>No effect on platelet function</li> <li>Cardiovascular and kidney risks are dose-related and may be similar to nonselective NSAIDs</li> <li>May be tolerated by patients with AERD or pseudoallergic reactions (eg, asthma, rhinosinusitis) who cannot take other NSAIDs; refer to UpToDate topic reviews of allergic and pseudoallergic reactions to NSAIDs</li> </ul> </td> </tr> <tr> <td class="indent1">Etoricoxib (not available in the United States)</td> <td>30 to 60 mg once daily</td> <td> <p>60 mg (chronic pain and inflammation)</p> 120 mg (acute pain for up to 8 days)</td> <td> <ul> <li>May be associated with more frequent and severe dose-related cardiovascular effects (eg, hypertension)</li> <li>Other risks and benefits similar to celecoxib</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Non-NSAID analgesic</td> </tr> <tr> <td class="indent1">Acetaminophen <span class="nowrap_whitespace">(paracetamol)<sup>Δ</sup></span></td> <td> <p>325 to 650 mg every 4 to 6 hours</p> <p>or</p> 1000 mg every 6 hours up to 3 times daily</td> <td> <p>3000 mg</p> <p>4000 mg in selected medically supervised patients</p> Avoid or use a lower total daily dose (maximum 2000 mg) in older adults, patients at increased risk for hepatotoxicity (eg, regular alcohol use, malnourished), or patients with organ dysfunction</td> <td> <ul> <li>Effective for noninflammatory pain; may decrease opioid requirements</li> <li>Doses ≤2000 mg per day do not appear to increase risk of serious GI <span class="nowrap_whitespace">complications<sup>[3]</sup></span></li> <li>Does not alter platelet function</li> <li>Can cause hepatotoxicity in chronic or acute overdose</li> <li>To avoid overdose, warn patients about acetaminophen content in combination prescription (eg, oxycodone-acetaminophen) and nonprescription (OTC) preparations</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>NSAIDs are useful for treatment of acute and chronic painful and inflammatory conditions and may reduce opioid requirements. The indications for use of NSAIDs in specific disorders, adverse effects, and toxicities are presented in the relevant UpToDate topics including reviews of NSAID-associated adverse cardiovascular effects, gastroduodenal toxicity, acute kidney injury, etc.</p>
<p>UpToDate contributors generally avoid use of NSAIDs, or use them with particular caution and at reduced doses, in older adults and patients (regardless of age) with existing or increased risk for cardiovascular, GI, or kidney disease. Concurrent gastroprotection (eg, a proton pump inhibitor) may be warranted. For information on gastroprotective strategies, including use of selective COX-2 inhibitors and other options, refer to the UpToDate topic reviews of COX-2 selective NSAIDs and NSAIDs (including aspirin) and primary prevention of gastroduodenal toxicity.</p>
<p>Short- to moderate-acting NSAIDs (eg, naproxen, ibuprofen) are preferred for most patients. Use the lowest effective dose for the shortest duration of time. For chronic inflammatory conditions, a trial of ≥2 weeks is advised to assess full efficacy. For patients who experience an inadequate response to an NSAID of 1 class, it is reasonable to substitute an NSAID of another class.</p>
<p>Dosing in this table is for immediate-release preparations in patients with normal organ (eg, kidney) function. For treatment of acute pain, a loading dose of some NSAIDs may be used; refer to Lexicomp drug monographs.</p>
Drug interactions may be determined by use of the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</div><div class="graphic_footnotes"><p>AERD: aspirin-exacerbated respiratory disease; CNS: central nervous system; COX-2: cyclooxygenase, isoform 2; GI: gastrointestinal; OTC: over the counter.</p>
<p>* Nonselective NSAIDs reversibly inhibit platelet function, with some exceptions noted above.</p>
<p>¶ Also available as a topical agent.</p>
Δ Also available for parenteral use.</div><div class="graphic_reference">References:
<ol>
<li>Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33:435.</li>
<li>Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet 2013; 382:769.</li>
<li>McCrae JC, Morrison EE, MacIntyer IM, et al. Long-term adverse effects of paracetamol – a review. Br J Clin Pharmacol 2018; 84:2218.</li>
</ol>
<p class="extra_spacing_top">Adapted from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All rights reserved.</p></div><div id="graphicVersion">Graphic 70067 Version 71.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
